ACETO Corp (ACET) Unit Launches Generic Ditropan XL Tablets
- Japan's Nikkei posts biggest point gain for fiscal year
- Citi downgrades tech stocks as its flagship indicator signals 'euphoria' levels
- UBS sees 5 warnings signals on semiconductor chip stocks
- 2 reasons why Tesla stock fell on Thursday
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- AMC Entertainment (AMC) Enters $250M ATM Agreement
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
ACETO Subsidiary, Rising Pharmaceuticals, to Launch Oxybutynin Chloride Extended-Release Tablets, USP
November 14, 2016 9:45 AM ESTPORT WASHINGTON, N.Y., Nov. 14, 2016 (GLOBE NEWSWIRE) -- ACETO Corporation (NASDAQ: ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, Inc., its finished dosage form generics subsidiary, is launching Oxybutynin Chloride Extended-Release Tablets, USP, an FDA-approved generic version of Janssen Pharmaceuticals, Inc.s Ditropan XL Tablets®.
According to IMS Health data, U.S. market sales for Oxybutynin Chloride Extended-Release Tablets, USP, which is used in the treatment of overactive bladder, were... More